Mediterr J Rheumatol 2016;27(2):40-7
Evaluation of liver fibrosis by transient elastography (FibroScan®) in rheumatic patients during methotrexate treatment
Authors Information

1: 2nd Department of Medicine and Laboratory, National University of Athens Medical School, Hippokration General Hospital, Athens, Greece

2: Department of Radiology, National University of Athens Medical School, Aretaeio University Hospital, Athens, Greece

3: Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National University of Athens Medical School, Athens, Greece

  1. Singh J A, Furst D E, Bharat A, Curtis J R, Kavanaugh A F, Kremer J M, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
  2. Smolen J S, Landewe R, Breedveld F C, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
  3. Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P, et al. [The liver and methotrexate]. [Article in French] Gastroenterol Clin Biol 2008;32:134-42.
  4. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
  5. Kremer J M, Alarcon G S, Lightfoot R W, Jr., Willkens R F, Furst D E, Williams H J, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
  6. Te H S, Schiano T D, Kuan S F, Hanauer S B, Conjeevaram H S, Baker A L. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95:3150-6.
  7. Visser K, Katchamart W, Loza E, Martinez-Lopez J A, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
  8. Aithal G P, Haugk B, Das S, Card T, Burt A D, Record C O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004;19:391-9.
  9. Salliot C, van der H D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.
  10. Bravo A A, Sheth S G, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
  11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-57.
  12. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239-44.
  13. Manolakopoulos S, Triantos C, Bethanis S, Theodoropoulos J, Vlachogiannakos J, Cholongitas E, et al. Ultrasound-guided liver biopsy in real life: comparison of same-day prebiopsy versus real-time ultrasound approach. J Gastroenterol Hepatol 2007;22: 1490-3.
  14. de Ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol 2008;32:58-67.
  15. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009;29:242-7.
  16. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
  17. Wong V W, Vergniol J, Wong GL, Foucher J, Chan H L, Le B B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-62.
  18. Tsochatzis E A, Gurusamy K S, Ntaoula S, Cholongitas E, Davidson B R, Burroughs A K. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011;54:650-9.
  19. Papageorgiou M V, Papatheodoridis G V, Manolakopoulos S, Tsochatzis E, Kranidioti H, Kafiri G, et al. Elastography for hepatic fibrosis severity in chronic hepatitis B or C. Case Rep Gastroenterol 2011;5:63-72.
  20. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
  21. Sandrin L, Fourquet B, Hasquenoph J M, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-13.
  22. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato M F, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73.
  23. Lucidarme D, Foucher J, Le B B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009;49:1083-9.
  24. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-47.
  25. Visser K, van der Heijde D M. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009;27:1017-25.
  26. Rosenberg P, Urwitz H, Johannesson A, Ros A M, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:1111-8.
  27. Roenigk H H, Jr., Auerbach R, Maibach H I, Weinstein G D. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
  28. Saag K G, Teng G G, Patkar N M, Anuntiyo J, Finney C, Curtis J R, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
  29. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-302.
  30. Torres D M, Williams C D, Harrison S A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58.
  31. Laharie D, Seneschal J, Schaeverbeke T, Doutre M S, Longy-Boursier M, Pellegrin J L, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010;53:1035-40.
  32. Laharie D, Zerbib F, Adhoute X, Boue-Lahorgue X, Foucher J, Castera L, et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate. Aliment Pharmacol Ther 2006; 23: 1621-8.
  33. Barbero-Villares A, Mendoza Jimenez-Ridruejo J, Taxonera C, Lopez-Sanroman A, Pajares R, Bermejo F, et al. Evaluation of liver fibrosis by transient elastography (Fibroscan(R)) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012; 47: 575-9.
  34. Bray A P, Barnova I, Przemioslo R, Kennedy C T. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol 2012;166:1125-7.
  35. Barbero-Villares A, Mendoza J, Trapero-Marugan M, Gonzalez-Alvaro I, Dauden E, Gisbert J P, et al. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients. Med Clin (Barc) 2011;137: 637-9.
  36. Berends M A, Snoek J, de Jong E M, Van Krieken J H, de Knegt R J, van Oijen M G, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007; 27:639-45.
  37. Arena U, Stasi C, Mannoni A, Benucci M, Maddali-Bongi S, Cammelli D, et al. Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. Dig Liver Dis 2012;44:149-53.
  38. Lee S W, Park H J, Kim B K, Han K H, Lee S K, Kim S U, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012;14:R232.
  39. Seitz M, Reichenbach S, Moller B, Zwahlen M, Villiger P M, Dufour J F. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study. Ann Rheum Dis 2010;69:1148-50.